ABSTRACT 9,1 1-Dimethylmethano-11, 12-methano-16-(3-iodo-4-hydroxyphenyl)-13, 14-dihydro-13-aza-15a/3-w-tetranor-TXA2 (I-PTA-OH), a recently synthesized thromboxane (TX) A2/prostaglandin (PG) H2 receptor antagonist, was shown to be a competitive antagonist of human platelet aggregation induced by the stable endoperoxide analog U46619. This antagonism was due to competitive blockade of the platelet TXA2/PGH2 receptor since I-PTA-OH did not antagonize the first phase of ADP-induced aggregation which is TXA2/PGH2 independent, nor did it inhibit TXA2 synthesis. In addition, analysis of dose-response curves to U46619 (0.1 to 40 ,M) in the presence of increasing concentrations of I-PTA-OH (0.5 to 10 ,M) showed that I-PTA-OH produced a parallel rightward shift of the dose-response curve. Further analysis of the data in the form of a Schild plot yielded a straight line with a slope (m = 1.03) not significantly different from -1. These results are consistent with the notion that I-PTA-OH acts as a competitive antagonist of the TXA2/PGH2 receptor. Circulation 72, No. 6, 1202No. 6, -1207No. 6, , 1985 SINCE THE DISCOVERY of the prostaglandin (PG) endoperoxides PGG2 and PGH2 -3 and thromboxane (TX) A2,4 their actions on platelets and vascular smooth muscle have been the subject of numerous investigations. Initial studies were descriptive in nature, characterizing PGG2, PGH2, and TXA2 as potent vasoconstrictors2-7 and stimulators of platelet aggregation.3' Since the development of TX synthetase inhibitors, the potential roles of the PG endoperoxides and TXA2 in platelet aggregation'0 and in cardiovascular diseases`' have been studied. It was anticipated that this group of compounds could provide new therapeutic approaches for the treatment of a variety of cardiovascular diseases."
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More recently, the development of stable analogs of the PG endoperoxides and TXA2, which act as either mimics or antagonists of the actions of the naturally occurring eicosanoids, has provided tools for fundamental investigations into the mechanisms of action of these compounds and the nature of their receptors. Studies with the receptor antagonists have provided From the Departments of Pharmacology and Medicine, Medical University of South Carolina, and The Drug Science Foundation, Charleston. Supported in part by NIH grants HL 29566 and HL 07260. some preliminary evidence for more than one class of receptors. 12 Like the TX synthetase inhibitors, the receptor antagonists also provide the promise of potential new therapeutic approaches for the treatment of a variety of cardiovascular diseases."
This report provides information of the effects of 9,1 1 -dimethylmethano-1 1, 12-methano-16-(3-iodo-4-hydroxyphenyl)-13,14-dihydro-13-aza-15a,83-wtetranor-TXA2, (I-PTA-OH), a recently synthesized'3 TXA2/PGH2 receptor antagonist, on human platelet aggregation. This compound was originally synthesized for its potential to be radiolabeled with 1251 for radioligand binding studies. Current concepts concerning platelet and vascular TXA2/PGH2 receptors are also reviewed.
Materials and methods
Platelet aggregation. Blood obtained by venipuncture from four healthy male subjects who had not received any medication for 2 weeks before the study was collected into plastic syringes containing 3.8% trisodium citrate (9:1). Platelet-rich plasma (PRP) was prepared by centrifugation of whole blood at 100 g for 30 min at room temperature. The PRP (425 gtl) was added to individual silanized glass cuvettes. Platelet aggregation was monitored, by the method of Born, 14 in a Chronolog model 300 aggregometer (Havertown, PA) maintained at 370 C. Platelets were preincubated with 25 gl of indomethacin (10 ,uM) and 25 ,l of the antagonist, I-PTA-OH, 0.5 to 10 pM (figure 1) or vehicle for 1 min before the addition of 25 ,l of the aggregating agent, the stable endoperoxide analog U46619 (0.1 to 40 ,um). The aggregatory response was followed for 2 min. The percent aggregation was determined 1 min after the addition of U46619. The pA2 value for I-PTA-OH was determined by constructing dose-response curves to U46619 in the presence and absence of varied concentrations of I-PTA-OH, as previously described. '5, 16 I-PTA-OH was synthesized by a previously described method. ' '8 Statistics. iTXB2 levels in control (vehicle) and treated (10 p.M I-PTA-OH) platelet homogenates were compared with Student's t test for paired observations.'9
Results
To determine if I-PTA-OH was an antagonist of the platelet TXA2/PGH2 receptor, platelets were aggregated with U46619. The latter is considered to be a TXA2/PGH2 receptor agonist. I-PTA-OH produced a dose-dependent inhibition of U46619-induced platelet aggregation (figure 2). As shown in figure 3 , increasing concentrations of I-PTA-OH produced successive parallel shifts in the dose-response curves to U46619. The Schild plotl'5 16 of the data (figure 4) revealed a straight line with a slope not significantly different from -1. Thus, I-PTA-OH appears to be a competitive inhibitor of U46619-induced platelet aggregation. The pA2 value (6.68) yields a Kd of 208 nM for I-PTA-OH. I-PTA-OH had no effect on the first phase of ADP-induced aggregation.'2 I-PTA-OH (10 uM) did not have any significant effect on platelet TX synthetase, as assayed in human platelet homogenates. Sixty seconds after the addition of 1 mM arachidonic acid, iTXB2 was 6.5 ± 1.4 ng/mg protein in control samples and 6.4 + 1.9 ng/mg protein in 10 ,M I-PTA-OH-treated samples (n = 3, p > .05).
Discussion
Until recently characterization of TXA2/PGH2 receptors has been predominately by pharmacologic approaches. The use of radiolabeled ligands for characterization of the receptors has lagged behind the pharmacologic approach. The major reason for this has been the unavailability of a suitable radiolabeled ligand. In particular, these efforts have been hampered by the lack of molecules with high affinity for the putative receptors and that may be easily radiolabeled to high specific activity and retain biological activity. Figure 1 shows the ligands that have been synthesized and used for radioligand binding studies to date.
The first molecule to be synthesized and used for radioligand binding assays was As these studies progressed, structure-activity relationships among the various analogs examined became apparent. For example, the most potent derivatives, agonist or antagonist, possess bicyclic ring systems of a variety of types that not only confer biological activity but also lend stability to the molecules."-5 Some of these molecules include the pinane,33 40 carbocyclic,34 41 and sulfur-substituted isosteres42-5 among the TXA2 analogs and the azo,32 ether,3' and ethano46 analogs among the PGH2 derivatives. In general, the retention of electronegative atoms (O,S,N) in the bicyclic nucleus leads to agonist activity, while substitution to an all-carbon system results in both agonist (CTA2) and antagonist (PTA2) properties, depending upon the degree of substitution of the bicyclic ring system.33 45 However, a notable exception is 1la-carba-TXA2, which is an antagonist of human platelet aggregation but devoid of any activity in rat aorta. 4" Certain structural groupings among the side chains of the analogs examined also appear to be important. Among the agonists, both the presence and the orientation of the C-15 hydroxy group in the natural (S) configuration is crucial for activity as a mimetic. 41 analogs are agonists, while the parent compound acts as an antagonist.46 Likewise, many TXA2/PGH2 antagonists have undergone significant modifications distal to the C-15 position and retained antagonist activity.51'53 Our work with a series ofco-substituted congeners that are analogs ofI-PTA-OH and TXA2/PGH2 receptor antagonists indicate that the receptors in platelets and vascular smooth muscle are different. It was determined that the potency ratios of the compounds as antagonists of U46619-induced platelet aggregation or contraction of saphenous vein were significantly different in tissues from canine and human sources.12 Furthermore, while the 15(R)-and 15(S)-epimers of PTA-OH, I-PTA-OH, and ONO1 120 were equipotent as antagonists of U46619-induced platelet aggregation, there were differences in their potencies as inhibitors of U46619-induced canine saphenous vein contraction.50 This confirms the suggestion put forward by several other investigatorS6' 37, 42, 47, [54] [55] [56] that the receptors are different in platelets than in blood vessels.
In summary, pharmacologic approaches have begun to characterize the TXA2/PGH2 receptor(s) in platelets and vascular smooth muscle. Structure-activity relationships among the variety of analogs synthesized have implicated the existence of different TXA2/PGH2 receptors among platelets and vascular smooth muscle. The strongest evidence for this is the presence of agonist activity in vascular smooth muscle and antagonistic activity in platelets6' 37. 42 
